<SEC-DOCUMENT>0001213900-24-098574-index.html : 20241114
<SEC-HEADER>0001213900-24-098574.hdr.sgml : 20241114
<ACCEPTANCE-DATETIME>20241114172045
ACCESSION NUMBER:		0001213900-24-098574
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20241114
DATE AS OF CHANGE:		20241114
EFFECTIVENESS DATE:		20241114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oruka Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-283243
		FILM NUMBER:		241464394

	BUSINESS ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-606-7910

	MAIL ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARCA biopharma, Inc.
		DATE OF NAME CHANGE:	20090128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>ea0220598-s8_oruka.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
Document 1 - file: ea0220598-s8_oruka.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea022059801ex5-1_oruka.htm
<DESCRIPTION>OPINION OF GIBSON, DUNN & CRUTCHER LLP
<TEXT>
Document 2 - file: ea022059801ex5-1_oruka.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea022059801ex23-1_oruka.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
Document 3 - file: ea022059801ex23-1_oruka.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>ea022059801ex99-2_oruka.htm
<DESCRIPTION>FORM OF GRANT NOTICE FOR STOCK OPTION AND STANDARD TERMS AND CONDITIONS FOR STOCK OPTIONS UNDER THE ORUKA THERAPEUTICS, INC. 2024 STOCK INCENTIVE PLAN (DIRECTORS)
<TEXT>
Document 4 - file: ea022059801ex99-2_oruka.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>5
<FILENAME>ea022059801ex99-3_oruka.htm
<DESCRIPTION>FORM OF GRANT NOTICE FOR STOCK OPTION AND STANDARD TERMS AND CONDITIONS FOR STOCK OPTIONS UNDER THE ORUKA THERAPEUTICS, INC. 2024 STOCK INCENTIVE PLAN (EMPLOYEES)
<TEXT>
Document 5 - file: ea022059801ex99-3_oruka.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>ea022059801ex-fee_oruka.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
Document 6 - file: ea022059801ex-fee_oruka.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 7 - file: ex5-1_001.jpg

</DOCUMENT>
</SEC-DOCUMENT>